Skip to main content
EBOSY logo

EBOS Group Limited (EBOSY) Stock Price & Analysis

EBOS Group Limited (EBOSY) — price $22.68 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.37B.

Educational signal · not a buy or sell recommendation · How to read this

$22.68 $0.00 (0.00%) Market Cap $2.37B

EBOS Group Limited · EBOSY

EBOS Group Limited is a diversified healthcare and animal care company operating in Australia, Southeast Asia, and New Zealand. The company's segments include Healthcare and Animal Care, providing a range of products and services within these sectors.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PBH · Prestige Consumer Healthcare Inc. · 63 /100
  • GRDN · Guardian Pharmacy Services, Inc. · 96 /100
  • HSIC · Henry Schein, Inc. · 73 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$22.68
Change on the day0.00%
52-week range$19.66 – $46.64
Market capitalisation$2.37B—
Price / earnings (trailing)16.56
Shares traded on the day524

Price & events

Other perspectives

Council score for EBOS Group (EBOSY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Weak
ROE Neutral
Gross Margin Negative

Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 30, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is EBOS Group (EBOSY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. EBOS Group Limited (EBOSY) is the company analyzed here. It employs 5,700 people and is led by Adam Luke Hall. In Q4 FY2025 it reported revenue of A$6.81B and net income of A$102M. The market values it at $2.37B.

2 · Latest results

What do the latest results show for EBOS Group (EBOSY)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of A$6.81B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025A$6.81BA$102MA$1.96 (diluted)
Q2 FY2025A$6.64BA$123MA$2.40 (diluted)
Q4 FY2024A$6.09BA$102MA$2.02 (diluted)
Q2 FY2024A$6.40BA$118MA$2.42 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for EBOS Group (EBOSY)?

Short answer · as of

The distress and quality screens read Altman Z 2.25 · Piotroski F 4. Trailing ratios: ROE 8.0% · ROA 2.8% · current ratio 1.16 · earnings yield 5.9% · free-cash-flow yield 5.6%.

4 · What to check next?

What should you watch next at EBOS Group (EBOSY)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $14.02B · EPS 0.00 · 10 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$14.02B
EPS estimate
$0.00

Measured against a quoted price of $22.68 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EBOSY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported EBOSY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about EBOS Group (EBOSY)?

Read these with our analysis →

Investor Questions: EBOSY Stock

These answers are editorial: 1 of these 8 answers is drawn from the EBOSY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is EBOSY a good stock to buy?

Stock Expert AI does not rate EBOSY buy, sell or hold. EBOS Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the EBOSY stock price today?

The last price recorded for EBOS Group Limited (EBOSY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for EBOSY?

The main risks for EBOSY include regulatory changes in the healthcare sector, which could impact product approvals and pricing. Economic downturns could affect consumer spending on healthcare and pet products. Disruptions in the supply chain due to geopolitical events or natural disasters could also pose a risk.

What are the key factors to evaluate for EBOSY?

Evaluate EBOSY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does EBOSY data refresh on this page?

EBOSY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven EBOSY's recent stock price performance?

EBOS Group Limited (EBOSY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified revenue streams across healthcare and animal care. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider EBOSY overvalued or undervalued right now?

The trailing P/E of EBOS Group Limited (EBOSY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research EBOSY before investing?

Before investing in EBOS Group Limited (EBOSY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.